The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Amlodipine/Valsartan/Hydrochlorothiazide Rowex 10 mg/320 mg/25 mg Film-coated tablets



Rowex LtdPA0711/291/005

Main Information

Trade NameAmlodipine/Valsartan/Hydrochlorothiazide Rowex 10 mg/320 mg/25 mg Film-coated tablets
Active SubstancesAmlodipine besilate
Valsartan
Hydrochlorothiazide
Dosage FormFilm-coated tablet
Licence HolderRowex Ltd
Licence NumberPA0711/291/005

Group Information

ATC CodeC09DX Angiotensin II antagonists, other combinations
C09DX01 valsartan, amlodipine and hydrochlorothiazide

Status

License statusAuthorised
Licence Issued19/08/2019
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back